Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
with Pfizer, granting the pharmaceutical giant access to its Matrix-M adjuvant tech. This technology is designed to boost immune responses to vaccines and will be utilized by Pfizer for up to two infectious diseases. While Pfizer will oversee the development, manufacturing, and commercialization of the resulting products, Novavax remains responsible for the delivery and supply of the Matrix-M adjuvant itself. Earlier on January 10, Pfizer Inc. (NYSE: PFE) announced positive results from Cohort 3 of its pivotal BREAKWATER trial. This specific randomized cohort evaluated the BRAFTOVI regimen in combination with cetuximab and FOLFIRI for patients with previously untreated metastatic colorectal cancer harboring a BRAF V600E mutation. Photo by Robb Miller on Unsplash The study showed that adding the chemotherapy backbone to the BRAFTOVI regimen significantly increased response rates. The analysis showed an objective response rate of 64% for the BRAFTOVI combination, compared to 39% f
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today? [Seeking Alpha]Seeking Alpha
- Novavax (NASDAQ:NVAX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NVAX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- Will Licensing Novavax's Matrix-M Adjuvant Reshape Pfizer's (PFE) Vaccine Platform Strategy? [Yahoo! Finance]Yahoo! Finance
- Why Are Novavax (NVAX) Shares Soaring Today [Yahoo! Finance]Yahoo! Finance
- Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer [Yahoo! Finance]Yahoo! Finance
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 1/26/26 - Form 4
- 1/20/26 - Form 8-K
- 1/12/26 - Form 8-K
- NVAX's page on the SEC website